NeoIntercal
Induction Therapy With Intercalated Tyrosine Kinase Inhibitor (TKI) and Chemotherapy in NSCLC With Activating Epidermal Growth Factor Receptor (EGFR) Mutation in Stages II-IIIB (NeoIntercal)
II
interventionell
National
Gefitinib (Iressa®)
Status: Studie beendet
Zeitraum
2015
2018
Zentren
Keine Zentren gesucht
Patienten
1
24.01.2026
Klinische Settings
II, IIIB
neoadjuvant
kurativ
Identifier
AIO-TRK-0214
AIO-TRK-0214
2014-005595-28
Kontakt
Leitung
Prof. Dr. med. Frank Griesinger
Ansprechpartner*in
AIO-Studien-gGmbH
Telefon +49 30 814534433
E-Mail info@aio-studien-ggmbh.de